BioNTech makes a splash with $10B+ projection for 2021 Covid-19 vaccine sales
BioNTech, Pfizer’s relatively quiet German biotech partner for its Covid-19 vaccine, made noise on Tuesday with its earnings report, projecting about €10 billion ($11.5 billion) in vaccine revenue based on the currently signed supply contracts for about 1.4 billion doses.
The €10 billion projection for the growing company, founded by the husband and wife team of Ugur Sahin and Özlem Türeci, comes almost exactly a year after the company first announced its plans to join up with Pfizer and bring its mRNA-based vaccine to fruition. That projection also dwarfs Pfizer’s original agreement to pay BioNTech $185 million upfront for the vaccine collaboration, even with the potential future milestone payments of up to $563 million.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters